Anthrax - Pipeline Review, H2 2018

  • ID: 4592432
  • Drug Pipelines
  • 106 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Altimmune Inc
  • Aradigm Corp
  • Crestone Inc
  • Emergent BioSolutions Inc
  • Hawaii Biotech Inc
  • iNtRON Biotechnology Inc
  • MORE
Anthrax - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H2 2018, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

Report Highlights:

This latest pipeline guide Anthrax - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 5, 20, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Altimmune Inc
  • Aradigm Corp
  • Crestone Inc
  • Emergent BioSolutions Inc
  • Hawaii Biotech Inc
  • iNtRON Biotechnology Inc
  • MORE
Introduction

Report Coverage

Anthrax - Overview

Anthrax - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anthrax - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anthrax - Companies Involved in Therapeutics Development

Altimmune Inc

Aphios Corp

Aradigm Corp

BlueWillow Biologics Inc

Companhia Industrial Produtora de Antibioticos SA

Crestone Inc

Dynavax Technologies Corp

Emergent BioSolutions Inc

GC Pharma

Hawaii Biotech Inc

iBio Inc

iNtRON Biotechnology Inc

Pfenex Inc

Protein Potential LLC

ProThera Biologics Inc

Soligenix Inc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

VLP Biotech Inc

Anthrax - Drug Profiles

anthrax (virus like particles) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anthrax + plague vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anthrax vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anthrax vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anthrax vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anthrax vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anthrax vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-7909 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BDM-I - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ciprofloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPN-1311 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPX-Anthrax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DV-230F - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-1109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GreAnPla - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GREANX - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Marinus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Anthrax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Anthrax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nasoshield - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBI-220 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Inhibit Furin for Anthrax and Bacterial Sepsis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Px-563L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

raxibacumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzymes to Disrupt Bacterial Cell Wall for Inhalational Anthrax Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins for Anthrax and Methicillin Resistant Staphylococcus Aureus (MRSA) Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RiVax + SGX-204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rPA-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPA-563 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Anthrax Toxin and Alpha Hemolysin for Anthrax and Staphylococcal aureus Pneumonia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial Infections and Bone Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SparVax-L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-271 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anthrax - Dormant Projects

Anthrax - Discontinued Products

Anthrax - Product Development Milestones

Featured News & Press Releases

Mar 12, 2018: Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program

Dec 11, 2017: Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial

Jun 19, 2017: NanoBio And Porton Biopharma Receive Approval To Advance Next Generation Anthrax Vaccine

Mar 28, 2017: Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield

Aug 08, 2016: Pfenex Announces Positive Anthrax Vaccine Study Results

Jun 22, 2016: U.S. Government Issues Solicitation Notices Providing Path to Achieve a Stockpile to Protect 25 Million People Through Procurement of Up to 56.4 Million Doses of NuThrax Vaccines

Aug 17, 2015: Pfenex Awarded HHS Contract Valued At Up To $143.5 Million For The Advanced Development Of Next Generation Anthrax Vaccine

Mar 24, 2015: Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax Vaccine

Jan 28, 2015: Immunovaccine Study Demonstrates Early Protection Against Anthrax with Single Dose Experimental Vaccines

Dec 29, 2014: Soligenix Announces Publication of Combination Ricin/Anthrax Vaccine Data

Dec 22, 2014: Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L

Oct 21, 2014: Immunovaccine Demonstrates Protection Against Lethal Anthrax Challenge with Rapid Acting, Single Dose Vaccine

Sep 08, 2014: Emergent BioSolutions Awarded Contract to Develop a Dry Formulation of NuThrax, a Next Generation Anthrax Vaccine

Apr 01, 2014: Immunovaccine and Pfenex Report Positive Results From Single Dose Anthrax Vaccine Studies

Feb 04, 2014: Hawaii Biotech Awarded Anthrax Anti-toxin Grant By National Institute Of Allergy And Infectious Diseases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Anthrax, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Anthrax - Pipeline by Altimmune Inc, H2 2018

Anthrax - Pipeline by Aphios Corp, H2 2018

Anthrax - Pipeline by Aradigm Corp, H2 2018

Anthrax - Pipeline by BlueWillow Biologics Inc, H2 2018

Anthrax - Pipeline by Companhia Industrial Produtora de Antibioticos SA, H2 2018

Anthrax - Pipeline by Crestone Inc, H2 2018

Anthrax - Pipeline by Dynavax Technologies Corp, H2 2018

Anthrax - Pipeline by Emergent BioSolutions Inc, H2 2018

Anthrax - Pipeline by GC Pharma, H2 2018

Anthrax - Pipeline by Hawaii Biotech Inc, H2 2018

Anthrax - Pipeline by iBio Inc, H2 2018

Anthrax - Pipeline by iNtRON Biotechnology Inc, H2 2018

Anthrax - Pipeline by Pfenex Inc, H2 2018

Anthrax - Pipeline by Protein Potential LLC, H2 2018

Anthrax - Pipeline by ProThera Biologics Inc, H2 2018

Anthrax - Pipeline by Soligenix Inc, H2 2018

Anthrax - Pipeline by Syntiron LLC, H2 2018

Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2018

Anthrax - Pipeline by VLP Biotech Inc, H2 2018

Anthrax - Dormant Projects, H2 2018

Anthrax - Dormant Projects, H2 2018 (Contd..1), H2 2018

Anthrax - Dormant Projects, H2 2018 (Contd..2), H2 2018

Anthrax - Dormant Projects, H2 2018 (Contd..3), H2 2018

Anthrax - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Anthrax, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Altimmune Inc
  • Aphios Corp
  • Aradigm Corp
  • BlueWillow Biologics Inc
  • Companhia Industrial Produtora de Antibioticos SA
  • Crestone Inc
  • Dynavax Technologies Corp
  • Emergent BioSolutions Inc
  • GC Pharma
  • Hawaii Biotech Inc
  • iBio Inc
  • iNtRON Biotechnology Inc
  • Pfenex Inc
  • Protein Potential LLC
  • ProThera Biologics Inc
  • Soligenix Inc
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc
  • VLP Biotech Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll